L'Oréal tri-partnership for “new generation of bio-based ingredients”



Leading beauty multinational L’Oréal Groupe has signed a tri-party agreement with French startup Abolis Biotechnologies and the German ingredients manufacturer Evonik​ to “provide turnkey solutions for biotech innovation.”  

The businesses said that the partnership will “support an end-to-end program to develop a new generation of bio-based ingredients.”  

L’Oréal Groupe, which invests over than €1bn in R&I every year, participated in Abolis’s €35m Series A funding round, as did Evonik.  

The new agreement will enable purpose-made, sustainable ingredients to be produced at the scale needed to satisfy global demand. 

It will also help to accelerate L’Oréal’s commitments that prioritise bio-based ingredients in its beauty formulations.  

Industrial biotechnology and microbiome can impact multiple actives

Abolis is a biotech startup based in Genopole, France, that has unique expertise in tailor-made industrial solutions based on microorganisms for a wide range of industries including food, healthcare and cosmetics.  

The new investment will allow the startup to expand its capabilities to develop microbe-powered solutions that will help industries transition to more sustainable business models.  

The two companies had previously collaborated in 2020 and this led to an extended lab set-up in 2022.  

CEO at Abolis Biotechnologies, Cyrille Pauthenier, said that “industrial biotechnology and microbiome solutions are key technologies for a 100% biobased cosmetic formulation,” as well as a “new frontier for new actives and skin gentle solutions for anti-ageing and skin dysbiosis, and haircare.” 



Source link

Scroll to Top